Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Sell
19
AMPH Quote, Financials, Valuation and Earnings
Last price:
$23.32
Seasonality move
:
12.49%
Day range:
$23.08 - $23.62
52-week range:
$22.64 - $53.96
Dividend yield:
0%
P/E ratio:
7.63x
P/S ratio:
1.66x
P/B ratio:
1.52x
Volume:
735K
Avg. volume:
676.8K
1-year change:
-41.7%
Market cap:
$1.1B
Revenue:
$732M
EPS (TTM):
$3.06
Analysts' Opinion
-
Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.00, Amphastar Pharmaceuticals has an estimated upside of 67.02% from its current price of $23.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $23.35.
Fair Value
-
According to the consensus of 5 analysts, Amphastar Pharmaceuticals has 67.02% upside to fair value with a price target of $39.00 per share.
AMPH vs. S&P 500
-
Over the past 5 trading days, Amphastar Pharmaceuticals has overperformed the S&P 500 by 0.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amphastar Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amphastar Pharmaceuticals has grown year-over-year revenues for 20 quarters straight. In the most recent quarter Amphastar Pharmaceuticals reported revenues of $186.5M.
Earnings Growth
-
Amphastar Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Amphastar Pharmaceuticals reported earnings per share of $0.74.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
1.66x
EV / EBIT:
6.78x
EV / Revenue:
2.04x
PEG ratio (5yr expected):
0.41x
EV / Free cash flow:
8.66x
Price / Operating cash flow:
7.05x
Enterprise value / EBITDA:
5.38x
Gross Profit (TTM):
$373.9M
Return On Assets:
10.36%
Net Income Margin (TTM):
21.79%
Return On Equity:
22.89%
Return On Invested Capital:
12.36%
Operating Margin:
24.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $499M | $644.4M | $732M | $178.1M | $186.5M | |
| Gross Profit | $248.9M | $351.1M | $373.9M | $96.1M | $86.6M | |
| Operating Income | $107.5M | $197M | $205.4M | $54M | $45.1M | |
| EBITDA | $146.2M | $240.3M | $277.3M | $64.6M | $65.1M | |
| Diluted EPS | $1.76 | $2.58 | $3.06 | $0.68 | $0.74 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $279.7M | $318.1M | $378.3M | $489.6M | $534.1M | |
| Total Assets | $631.2M | $671.5M | $742M | $1.5B | $1.6B | |
| Current Liabilities | $112.2M | $103.8M | $94.9M | $225.4M | $173.8M | |
| Total Liabilities | $182.5M | $226M | $213.3M | $873.5M | $845.2M | |
| Total Equity | $448.7M | $445.5M | $528.7M | $639.4M | $732.3M | |
| Total Debt | $46.4M | $77M | $75.9M | $590M | $601.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $89.2M | $183.5M | $213.4M | $23.9M | $29M | |
| Cash From Investing | -$32.8M | -$649.1M | -$124.9M | -$103M | -$35.7M | |
| Cash From Financing | -$26.4M | $454.1M | -$81M | -$47.1M | -$33.8M | |
| Free Cash Flow | $65.1M | $145.3M | $172.3M | $14.4M | $16.6M | |
AMPH
Sector
Market Cap
$1.1B
$35M
Price % of 52-Week High
43.28%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
5.25%
-0.81%
1-Year Price Total Return
-41.7%
-41.61%
Beta (5-Year)
0.791
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$23.87
200-day SMA
Sell
Level
$39.74
Bollinger Bands (100)
Sell
Level
27.52 - 40.6
Chaikin Money Flow
Buy
Level
3M
20-day SMA
Sell
Level
$26.26
Relative Strength Index (RSI14)
Sell
Level
32.79
ADX Line
Sell
Level
42.22
Williams %R
Buy
Level
-89.2879
50-day SMA
Sell
Level
$28.41
MACD (12, 26)
Sell
Level
-1.58
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
12.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9585)
Buy
CA Score
(Annual)
Level (0.1049)
Buy
Beneish M-Score
(Annual)
Level (-2.4601)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.4574)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Stock Forecast FAQ
In the current month, AMPH has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AMPH average analyst price target in the past 3 months is $39.00.
-
Where Will Amphastar Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amphastar Pharmaceuticals share price will rise to $39.00 per share over the next 12 months.
-
What Do Analysts Say About Amphastar Pharmaceuticals?
Analysts are divided on their view about Amphastar Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amphastar Pharmaceuticals is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Amphastar Pharmaceuticals's Price Target?
The price target for Amphastar Pharmaceuticals over the next 1-year time period is forecast to be $39.00 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AMPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amphastar Pharmaceuticals is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMPH?
You can purchase shares of Amphastar Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amphastar Pharmaceuticals shares.
-
What Is The Amphastar Pharmaceuticals Share Price Today?
Amphastar Pharmaceuticals was last trading at $23.32 per share. This represents the most recent stock quote for Amphastar Pharmaceuticals. Yesterday, Amphastar Pharmaceuticals closed at $23.35 per share.
-
How To Buy Amphastar Pharmaceuticals Stock Online?
In order to purchase Amphastar Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
